CU20070002A7 - Proceso para la preparación y uso de una vacuna bivalente contra la adicción a la morfina-heroína - Google Patents
Proceso para la preparación y uso de una vacuna bivalente contra la adicción a la morfina-heroínaInfo
- Publication number
- CU20070002A7 CU20070002A7 CU20070002A CU20070002A CU20070002A7 CU 20070002 A7 CU20070002 A7 CU 20070002A7 CU 20070002 A CU20070002 A CU 20070002A CU 20070002 A CU20070002 A CU 20070002A CU 20070002 A7 CU20070002 A7 CU 20070002A7
- Authority
- CU
- Cuba
- Prior art keywords
- morphine
- addiction
- structural
- revealed
- heroin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/141111—Diverse hetero atoms in same or different rings [e.g., alkaloids, opiates, etc.]
Abstract
Se revela el diseno estructural, métodos de preparación y composición química de dos formulaciones estructurales de vacunas bivalentes contra la adicción a morfina-heroína (morfina-6-hemiscuccinil-EDC-TFCS-toxoide tetánico y 3-0-carboximetilmorfina-EDC-TFCS-toxoide tetánico, adecuados para su empleo en la vacunación en el humano, los cuales son capaces de inducir la síntesis de anticuerpos policlonales contra este opiáceo adictivo y contra su análogo estructural la heroína, a través de su administración repetida in vivo, en un esquema de vacunación activa en estudios de fase preclínica en el modelo animal del roedor. También se revela el paradigma de vacunación activa con estos inmunógenos, los cuales son capaces de inducir una respuesta inmunológica humoral de altos títulos de anticuerpos específicos séricos consolidada con memoria a largo plazo contra esta dos drogas. En forma complementaria, también se revela que estas composiciones químicas de inmunógenos tienen capacidades de conferir inmunoprotección eficaz contra la adicción a la morfina y su congénere estructural altamente activo, la heroína, en el modelo farmacológico de autoadministración intravenosa adictiva de estos dos opiáceos en el roedor. Finalmente, se discuten las implicaciones terapéuticas del empleo potencial ulterior de estos inmunoconjugados en esquemas de vacunación activa para el tratamiento de la adicción a estas dos drogasen el humano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA04006617A MXPA04006617A (es) | 2004-07-07 | 2004-07-07 | Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina. |
PCT/MX2005/000049 WO2006004390A2 (es) | 2004-07-07 | 2005-07-05 | Proceso para la preparación y uso de una vacuna bivalente contra la adicción a la morfina-heroína |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20070002A7 true CU20070002A7 (es) | 2009-09-08 |
CU23917B1 CU23917B1 (es) | 2013-07-31 |
Family
ID=35431510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2007000002A CU23917B1 (es) | 2004-07-07 | 2007-01-05 | Proceso para la preparación y uso de una vacuna bivalente contra la adicción a la morfina-heroína |
Country Status (15)
Country | Link |
---|---|
US (4) | US8008457B2 (es) |
EP (1) | EP1767221B1 (es) |
AR (1) | AR049962A1 (es) |
BR (1) | BRPI0513024A (es) |
CA (1) | CA2573042C (es) |
CU (1) | CU23917B1 (es) |
CY (1) | CY1114673T1 (es) |
DK (1) | DK1767221T3 (es) |
ES (1) | ES2435769T3 (es) |
MX (1) | MXPA04006617A (es) |
PE (1) | PE20060377A1 (es) |
PL (1) | PL1767221T3 (es) |
PT (1) | PT1767221E (es) |
SI (1) | SI1767221T1 (es) |
WO (1) | WO2006004390A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04006617A (es) | 2004-07-07 | 2006-01-12 | Inst Nac De Psiquiatria Ramon | Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina. |
US8170546B2 (en) | 2006-03-22 | 2012-05-01 | Broadcom Corporation | Client device characterization of other client device transmissions and reporting of signal qualities to access point(s) |
EP1982729A1 (en) * | 2007-04-20 | 2008-10-22 | Cytos Biotechnology AG | Vaccination Regimen for B-Cell Vaccines |
WO2011041483A2 (en) * | 2009-09-30 | 2011-04-07 | Toxcure, Inc. | Use of botulinum neurotoxin to treat substance addictions |
CN102002049B (zh) * | 2010-10-12 | 2013-01-02 | 北京大学 | 一种抗原及其制备方法与应用 |
CN102539764A (zh) * | 2010-12-27 | 2012-07-04 | 北京库尔科技有限公司 | 盐酸哌替啶检测试剂盒及其制备方法 |
EP2717057A1 (en) * | 2012-10-04 | 2014-04-09 | Cisbio Bioassays | Morphine-6-glucuronide derivatives, immunogens and immunoassay |
RU2526807C2 (ru) * | 2012-11-28 | 2014-08-27 | Общество с ограниченной ответственностью "ДИАМЕДИКА" ООО "ДИАМЕДИКА" | Синтетический иммуноген для защиты от токсического действия наркотических и психоактивных веществ |
EP2970320B1 (en) | 2013-03-15 | 2020-10-28 | Johnson Matthey Public Limited Company | Morphine sulfate methanolic solvate, processes for making same and related compositions and methods for treating pain |
US10262505B1 (en) * | 2013-12-03 | 2019-04-16 | Ca, Inc. | Anti-skimming solution |
WO2017127390A1 (en) | 2016-01-21 | 2017-07-27 | The Scripps Research Institute | Synthetic opioid vaccine |
WO2019094528A1 (en) | 2017-11-09 | 2019-05-16 | The Scripps Research Institute | An improved heroin vaccine |
WO2020012245A1 (en) | 2018-07-13 | 2020-01-16 | Alkermes Pharma Ireland Limited | Thienothiophene-naltrexone prodrugs for long-acting injectable compositions |
WO2020012248A1 (en) | 2018-07-13 | 2020-01-16 | Alkermes Pharma Ireland Limited | Novel naphthylenyl compounds for long-acting injectable compositions and related methods |
WO2020094634A1 (en) | 2018-11-05 | 2020-05-14 | Alkermes Pharma Ireland Limited | Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods |
RU2703494C1 (ru) * | 2018-11-12 | 2019-10-18 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Моноклональное антитело 6g1 к производным морфина |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH678394A5 (es) | 1990-08-22 | 1991-09-13 | Cerny Erich H | |
US6210677B1 (en) * | 1993-01-29 | 2001-04-03 | Robert C. Bohannon | Method to reduce the physiologic effects of drugs on mammals |
US5876727A (en) * | 1995-03-31 | 1999-03-02 | Immulogic Pharmaceutical Corporation | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
DE69637089T2 (de) | 1995-03-31 | 2008-01-17 | Xenova Research Ltd., Slough | Hapten-Träger-Konjugate zur Anwendung in der Drogen-Missbrauchs-Therapie |
US20020032316A1 (en) * | 1995-03-31 | 2002-03-14 | Cantab Pharmaceuticals Research Limited | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
CN1069544C (zh) | 1998-04-24 | 2001-08-15 | 昆明市生物技术工程研究中心 | 人用阿片类毒品戒毒疫苗 |
AU2004215125B2 (en) * | 2003-02-26 | 2011-01-06 | Institute For Research In Biomedicine | Monoclonal antibody production by EBV transformation of B cells |
MXPA04006617A (es) | 2004-07-07 | 2006-01-12 | Inst Nac De Psiquiatria Ramon | Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina. |
-
2004
- 2004-07-07 MX MXPA04006617A patent/MXPA04006617A/es active IP Right Grant
-
2005
- 2005-07-05 PE PE2005000780A patent/PE20060377A1/es active IP Right Grant
- 2005-07-05 PT PT57619173T patent/PT1767221E/pt unknown
- 2005-07-05 CA CA2573042A patent/CA2573042C/en active Active
- 2005-07-05 AR ARP050102788A patent/AR049962A1/es not_active Application Discontinuation
- 2005-07-05 US US11/632,085 patent/US8008457B2/en not_active Expired - Fee Related
- 2005-07-05 PL PL05761917T patent/PL1767221T3/pl unknown
- 2005-07-05 ES ES05761917T patent/ES2435769T3/es active Active
- 2005-07-05 SI SI200531802T patent/SI1767221T1/sl unknown
- 2005-07-05 EP EP05761917.3A patent/EP1767221B1/en active Active
- 2005-07-05 DK DK05761917.3T patent/DK1767221T3/da active
- 2005-07-05 BR BRPI0513024-7A patent/BRPI0513024A/pt not_active Application Discontinuation
- 2005-07-05 WO PCT/MX2005/000049 patent/WO2006004390A2/es active Application Filing
-
2007
- 2007-01-05 CU CU2007000002A patent/CU23917B1/es active IP Right Grant
-
2011
- 2011-07-14 US US13/182,634 patent/US8357375B2/en active Active
-
2012
- 2012-12-10 US US13/709,507 patent/US8916170B2/en active Active
-
2013
- 2013-11-20 CY CY20131101023T patent/CY1114673T1/el unknown
-
2014
- 2014-11-06 US US14/535,007 patent/US20150064212A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
SI1767221T1 (sl) | 2014-01-31 |
CA2573042C (en) | 2013-01-15 |
US20150064212A1 (en) | 2015-03-05 |
US20080241183A1 (en) | 2008-10-02 |
EP1767221B1 (en) | 2013-08-21 |
BRPI0513024A (pt) | 2008-04-22 |
EP1767221A2 (en) | 2007-03-28 |
US20130236478A1 (en) | 2013-09-12 |
US20110318381A1 (en) | 2011-12-29 |
US8357375B2 (en) | 2013-01-22 |
DK1767221T3 (da) | 2013-11-25 |
PL1767221T3 (pl) | 2014-02-28 |
CY1114673T1 (el) | 2016-10-05 |
WO2006004390A2 (es) | 2006-01-12 |
PE20060377A1 (es) | 2006-05-05 |
PT1767221E (pt) | 2013-11-27 |
MXPA04006617A (es) | 2006-01-12 |
US8008457B2 (en) | 2011-08-30 |
CU23917B1 (es) | 2013-07-31 |
CA2573042A1 (en) | 2006-01-12 |
ES2435769T3 (es) | 2013-12-23 |
WO2006004390A3 (es) | 2006-09-21 |
AR049962A1 (es) | 2006-09-20 |
US8916170B2 (en) | 2014-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20070002A7 (es) | Proceso para la preparación y uso de una vacuna bivalente contra la adicción a la morfina-heroína | |
Dykman | Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases | |
Xia et al. | Chitosan-based mucosal adjuvants: Sunrise on the ocean | |
Suh et al. | Microneedle patches for vaccine delivery | |
Kim et al. | Enabling skin vaccination using new delivery technologies | |
Alving et al. | Adjuvants for vaccines to drugs of abuse and addiction | |
Scheiblhofer et al. | Skin vaccination via fractional infrared laser ablation-Optimization of laser-parameters and adjuvantation | |
Kaurav et al. | Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage | |
Zhu et al. | A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines | |
McCormick et al. | Chemical conjugate TMV− peptide bivalent fusion vaccines improve cellular immunity and tumor protection | |
JP2013536240A5 (es) | ||
US8980276B2 (en) | Conjugates for the prevention or treatment of nicotine addiction | |
ES2565578T3 (es) | Vacunas contra el cáncer que contienen epítopos de antígeno oncofetal | |
Wu et al. | Overview of vaccine adjuvants | |
CN111212846A (zh) | 三萜皂苷类似物 | |
Shakya et al. | A comparative study of microneedle-based cutaneous immunization with other conventional routes to assess feasibility of microneedles for allergy immunotherapy | |
Ungaro et al. | VLPs and particle strategies for cancer vaccines | |
Abdellatif et al. | Lipid nanoparticles technology in vaccines: Shaping the future of prophylactic medicine | |
Shende et al. | Combined vaccines for prophylaxis of infectious conditions | |
CY1121145T1 (el) | Συστημα χορηγησης φαρμακων για χορηγηση μιας υδατοδιαλυτης, κατιοντικης και αμφιφιλης φαρμακευτικως ενεργης ουσιας | |
ES2609839T3 (es) | Método de vacunación | |
Chen et al. | Maximizing TLR9 activation in cancer immunotherapy with dual-adjuvanted spherical nucleic acids | |
Edwards et al. | Exploiting unique features of microneedles to modulate immunity | |
Kim et al. | Influenza immunization with trehalose-stabilized virus-like particle vaccine using microneedles | |
EA201170569A1 (ru) | Лекарственное средство для повышения дозы противоаллергической вакцины |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent |